title: Pituitary peptides other than ACTH may not be aldosterone secretagogue in primary aldosteronism.
abstract: In order to elucidate whether pituitary peptides other than ACTH which are derived from the proopiomelanocortin (POMC) are involved for aldosterone secretion in primary aldosteronism, we administered ovine corticotropin releasing factor (CRF), beta-endorphin and naloxone to seven patients with aldosterone producing adenoma. One hundred micrograms of CRF produced an augmented aldosterone response in patients with aldosteronism, while 500 micrograms of beta-endorphin infusion failed to cause any significant changes in neither normal subjects nor patients. An opioid antagonist, naloxone (10 mg, iv) produced no noticeable change in plasma aldosterone in normal subjects, while it caused a slight increase in patients with primary aldosteronism. Plasma cortisol increased to a similar degree in response to CRF and naloxone in normal subjects and patients. In three patients with isolated ACTH deficiency, neither aldosterone nor cortisol responded to these stimuli. The present results indicate that POMC-derived pituitary peptides other than ACTH are unlikely to participate in the aldosterone secretion in normal subjects or in patients with primary aldosteronism.
authors.affiliation: Second Department of Medicine, School of Medicine, Kanazawa University, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Miyamori
authors.forename: H
authors.initials: H
authors.lastname: Koshida
authors.forename: T
authors.initials: T
authors.lastname: Matsubara
authors.forename: R
authors.initials: R
authors.lastname: Soma
authors.forename: H
authors.initials: H
authors.lastname: Takasaki
authors.forename: S
authors.initials: S
authors.lastname: Okamoto
authors.forename: R
authors.initials: R
authors.lastname: Takeda
mesh_terms: D000236:Adenoma / Q000378:metabolism; D000310:Adrenal Gland Neoplasms / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000172:deficiency / Q000378:metabolism / Q000502:physiology*; D000328:Adult; D000450:Aldosterone / Q000097:blood*; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006929:Hyperaldosteronism / Q000097:blood* / Q000503:physiopathology; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology; D010907:Pituitary Hormones / Q000378:metabolism / Q000502:physiology*; D011333:Pro-Opiomelanocortin / Q000378:metabolism; D001615:beta-Endorphin / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D010907:Pituitary Hormones; D009270:Naloxone; D000450:Aldosterone; D001615:beta-Endorphin; D011333:Pro-Opiomelanocortin; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D006854:Hydrocortisone